ID   TIAM1_HUMAN             Reviewed;        1591 AA.
AC   Q13009; B7ZLR6; F5GZ53; Q17RT7;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   10-JUL-2007, sequence version 2.
DT   28-JUN-2023, entry version 202.
DE   RecName: Full=Rho guanine nucleotide exchange factor TIAM1 {ECO:0000305|PubMed:25684205};
DE   AltName: Full=T-lymphoma invasion and metastasis-inducing protein 1 {ECO:0000250|UniProtKB:Q60610};
DE            Short=TIAM-1 {ECO:0000250|UniProtKB:Q60610};
GN   Name=TIAM1 {ECO:0000303|PubMed:7731688, ECO:0000312|HGNC:HGNC:11805};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT HIS-844.
RC   TISSUE=Fetal brain;
RX   PubMed=7731688;
RA   Habets G.G.M., van der Kammen R.A., Stam J.C., Michiels F., Collard J.G.;
RT   "Sequence of the human invasion-inducing TIAM1 gene, its conservation in
RT   evolution and its expression in tumor cell lines of different tissue
RT   origin.";
RL   Oncogene 10:1371-1376(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10830953; DOI=10.1038/35012518;
RA   Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T., Park H.-S.,
RA   Toyoda A., Ishii K., Totoki Y., Choi D.-K., Groner Y., Soeda E., Ohki M.,
RA   Takagi T., Sakaki Y., Taudien S., Blechschmidt K., Polley A., Menzel U.,
RA   Delabar J., Kumpf K., Lehmann R., Patterson D., Reichwald K., Rump A.,
RA   Schillhabel M., Schudy A., Zimmermann W., Rosenthal A., Kudoh J.,
RA   Shibuya K., Kawasaki K., Asakawa S., Shintani A., Sasaki T., Nagamine K.,
RA   Mitsuyama S., Antonarakis S.E., Minoshima S., Shimizu N., Nordsiek G.,
RA   Hornischer K., Brandt P., Scharfe M., Schoen O., Desario A., Reichelt J.,
RA   Kauer G., Bloecker H., Ramser J., Beck A., Klages S., Hennig S.,
RA   Riesselmann L., Dagand E., Wehrmeyer S., Borzym K., Gardiner K.,
RA   Nizetic D., Francis F., Lehrach H., Reinhardt R., Yaspo M.-L.;
RT   "The DNA sequence of human chromosome 21.";
RL   Nature 405:311-319(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   VAL-1023.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   INTERACTION WITH RAC.
RC   TISSUE=Brain;
RX   PubMed=7753201; DOI=10.1038/375338a0;
RA   Michiels F., Habets G.G.M., Stam J.C., van der Kammen R.A., Collard J.G.;
RT   "A role for Rac in Tiam1-induced membrane ruffling and invasion.";
RL   Nature 375:338-340(1995).
RN   [5]
RP   CHROMOSOMAL LOCATION.
RX   PubMed=7736788; DOI=10.1159/000133989;
RA   Habets G.G.M., van der Kammen R.A., Jenkins N.A., Gilbert D.J.,
RA   Copeland N.G., Hagemeijer A., Collard J.G.;
RT   "The invasion-inducing TIAM1 gene maps to human chromosome band 21q22 and
RT   mouse chromosome 16.";
RL   Cytogenet. Cell Genet. 70:48-51(1995).
RN   [6]
RP   INTERACTION WITH BAIAP2.
RX   PubMed=15899863; DOI=10.1128/mcb.25.11.4602-4614.2005;
RA   Connolly B.A., Rice J., Feig L.A., Buchsbaum R.J.;
RT   "Tiam1-IRSp53 complex formation directs specificity of rac-mediated actin
RT   cytoskeleton regulation.";
RL   Mol. Cell. Biol. 25:4602-4614(2005).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-231, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-231, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [10]
RP   SUBCELLULAR LOCATION, AND SUBUNIT.
RX   PubMed=20332120; DOI=10.1242/jcs.059329;
RA   Lampugnani M.G., Orsenigo F., Rudini N., Maddaluno L., Boulday G.,
RA   Chapon F., Dejana E.;
RT   "CCM1 regulates vascular-lumen organization by inducing endothelial
RT   polarity.";
RL   J. Cell Sci. 123:1073-1080(2010).
RN   [11]
RP   INTERACTION WITH EPHA8.
RX   PubMed=20496116; DOI=10.1007/s10059-010-0075-2;
RA   Yoo S., Shin J., Park S.;
RT   "EphA8-ephrinA5 signaling and clathrin-mediated endocytosis is regulated by
RT   Tiam-1, a Rac-specific guanine nucleotide exchange factor.";
RL   Mol. Cells 29:603-609(2010).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-231, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [13]
RP   FUNCTION, UBIQUITINATION AT LYS-1404 AND LYS-1420, AND MUTAGENESIS OF
RP   LYS-1404 AND LYS-1420.
RX   PubMed=25684205; DOI=10.1016/j.molcel.2014.12.040;
RA   Genau H.M., Huber J., Baschieri F., Akutsu M., Doetsch V., Farhan H.,
RA   Rogov V., Behrends C.;
RT   "CUL3-KBTBD6/KBTBD7 ubiquitin ligase cooperates with GABARAP proteins to
RT   spatially restrict TIAM1-RAC1 signaling.";
RL   Mol. Cell 57:995-1010(2015).
RN   [14]
RP   STRUCTURE BY NMR OF 835-935.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the PDZ domain of T-cell lymphoma invasion and
RT   metastasis 1 variant.";
RL   Submitted (JUN-2006) to the PDB data bank.
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (1.30 ANGSTROMS) OF 841-930 IN COMPLEX WITH SYNTHETIC
RP   MODEL PEPTIDE, FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH SDC1
RP   AND CNTNAP4.
RX   PubMed=20361982; DOI=10.1016/j.jmb.2010.03.047;
RA   Shepherd T.R., Klaus S.M., Liu X., Ramaswamy S., DeMali K.A., Fuentes E.J.;
RT   "The Tiam1 PDZ domain couples to Syndecan1 and promotes cell-matrix
RT   adhesion.";
RL   J. Mol. Biol. 398:730-746(2010).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.98 ANGSTROMS) OF 429-702, AND INTERACTION WITH
RP   PARD3.
RX   PubMed=23832200; DOI=10.1107/s1744309113014206;
RA   Joshi M., Gakhar L., Fuentes E.J.;
RT   "High-resolution structure of the Tiam1 PHn-CC-Ex domain.";
RL   Acta Crystallogr. F 69:744-752(2013).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.54 ANGSTROMS) OF 841-930 IN COMPLEX WITH SDC1,
RP   MUTAGENESIS OF LYS-879 AND LYS-912, AND INTERACTION WITH CNTNAP4; SDC1 AND
RP   SDC3.
RX   PubMed=23395182; DOI=10.1016/j.str.2013.01.004;
RA   Liu X., Shepherd T.R., Murray A.M., Xu Z., Fuentes E.J.;
RT   "The structure of the Tiam1 PDZ domain/ phospho-syndecan1 complex reveals a
RT   ligand conformation that modulates protein dynamics.";
RL   Structure 21:342-354(2013).
RN   [18]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-678 AND VAL-1339.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [19]
RP   VARIANT HIS-1007.
RX   PubMed=22100072; DOI=10.1016/j.ajhg.2011.10.011;
RA   Aldahmesh M.A., Mohamed J.Y., Alkuraya H.S., Verma I.C., Puri R.D.,
RA   Alaiya A.A., Rizzo W.B., Alkuraya F.S.;
RT   "Recessive mutations in ELOVL4 cause ichthyosis, intellectual disability,
RT   and spastic quadriplegia.";
RL   Am. J. Hum. Genet. 89:745-750(2011).
RN   [20]
RP   VARIANTS NEDLDS CYS-23; VAL-328; ARG-382; PHE-862; VAL-1339 AND GLU-1547,
RP   AND INVOLVEMENT IN NEDLDS.
RX   PubMed=35240055; DOI=10.1016/j.ajhg.2022.01.020;
RA   Lu S., Hernan R., Marcogliese P.C., Huang Y., Gertler T.S., Akcaboy M.,
RA   Liu S., Chung H.L., Pan X., Sun X., Oguz M.M., Oztoprak U.,
RA   de Baaij J.H.F., Ivanisevic J., McGinnis E., Guillen Sacoto M.J.,
RA   Chung W.K., Bellen H.J.;
RT   "Loss-of-function variants in TIAM1 are associated with developmental
RT   delay, intellectual disability, and seizures.";
RL   Am. J. Hum. Genet. 109:571-586(2022).
CC   -!- FUNCTION: Guanyl-nucleotide exchange factor that activates RHO-like
CC       proteins and connects extracellular signals to cytoskeletal activities.
CC       Activates RAC1, CDC42, and to a lesser extent RHOA and their downstream
CC       signaling to regulate processes like cell adhesion and cell migration.
CC       {ECO:0000269|PubMed:20361982, ECO:0000269|PubMed:25684205}.
CC   -!- SUBUNIT: Component of the Par polarity complex, composed of at least
CC       phosphorylated PRKCZ, PARD3 and TIAM1. Interacts with NTRK2; mediates
CC       the activation of RAC1 by BDNF. Interacts with MAPK8IP2 and CD44 (By
CC       similarity). Interacts with BAIAP2. Interacts with EPHA8; regulates
CC       clathrin-mediated endocytosis of EPHA8. Interacts with PARD3. Interacts
CC       (via PDZ domain) with CNTNAP4, SDC1 and SDC3 (via C-terminus).
CC       {ECO:0000250, ECO:0000269|PubMed:15899863, ECO:0000269|PubMed:20332120,
CC       ECO:0000269|PubMed:20361982, ECO:0000269|PubMed:20496116,
CC       ECO:0000269|PubMed:23395182, ECO:0000269|PubMed:23832200,
CC       ECO:0000269|PubMed:7753201}.
CC   -!- INTERACTION:
CC       Q13009; O14936: CASK; NbExp=2; IntAct=EBI-1050007, EBI-1215506;
CC       Q13009; Q9C0A0-1: CNTNAP4; NbExp=2; IntAct=EBI-1050007, EBI-16035743;
CC       Q13009; P18827: SDC1; NbExp=5; IntAct=EBI-1050007, EBI-2855248;
CC       Q13009; P54763: Ephb2; Xeno; NbExp=3; IntAct=EBI-1050007, EBI-537711;
CC   -!- SUBCELLULAR LOCATION: Cell junction. Cell membrane; Peripheral membrane
CC       protein; Cytoplasmic side. Note=Detected at the boundary between cells
CC       with actin-rich protrusions (By similarity). Presence of KRIT1, CDH5
CC       and RAP1B is required for its localization to the cell junction.
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13009-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13009-2; Sequence=VSP_055865, VSP_055866;
CC   -!- TISSUE SPECIFICITY: Found in virtually all analyzed tumor cell lines
CC       including B- and T-lymphomas, neuroblastomas, melanomas and carcinomas.
CC   -!- DOMAIN: The first PH domain mediates interaction with membranes
CC       enriched in phosphoinositides. {ECO:0000250}.
CC   -!- PTM: Ubiquitinated. Undergoes 'Lys-48' ubiquitination at Lys-1404 and
CC       Lys-1420 by a CUL3(KBTBD6/7) E3 ubiquitin ligase complex composed of
CC       CUL3, RBX1, KBTBD6 and KBTBD7. 'Lys-48' ubiquitination at Lys-1404 and
CC       Lys-1420 triggers proteasomal degradation (PubMed:25684205).
CC       Ubiquitination at Lys-1404 and Lys-1420 by CUL3(KBTBD6/7) also requires
CC       the membrane-associated protein GABARAP and may therefore be spatially
CC       restricted within the cell (PubMed:25684205).
CC       {ECO:0000269|PubMed:25684205}.
CC   -!- DISEASE: Neurodevelopmental disorder with language delay and seizures
CC       (NEDLDS) [MIM:619908]: An autosomal recessive disorder characterized by
CC       global developmental delay, intellectual disability, speech delay, and
CC       seizures. Additional features may include axial hypotonia, peripheral
CC       hypertonia, hypothyroidism, and non-specific dysmorphic features or
CC       brain imaging abnormalities. {ECO:0000269|PubMed:35240055}. Note=The
CC       disease may be caused by variants affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the TIAM family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/42557/TIAM1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U16296; AAA98443.1; -; mRNA.
DR   EMBL; AP000246; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000247; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000248; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000249; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000250; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000251; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000563; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC117192; AAI17193.1; -; mRNA.
DR   EMBL; BC117196; AAI17197.1; -; mRNA.
DR   EMBL; BC143980; AAI43981.1; -; mRNA.
DR   CCDS; CCDS13609.1; -. [Q13009-1]
DR   RefSeq; NP_003244.2; NM_003253.2. [Q13009-1]
DR   RefSeq; XP_005261094.1; XM_005261037.1.
DR   RefSeq; XP_005261095.1; XM_005261038.2.
DR   RefSeq; XP_011528013.1; XM_011529711.1.
DR   RefSeq; XP_011528014.1; XM_011529712.1.
DR   RefSeq; XP_011528015.1; XM_011529713.1.
DR   RefSeq; XP_016883936.1; XM_017028447.1.
DR   RefSeq; XP_016883937.1; XM_017028448.1.
DR   RefSeq; XP_016883938.1; XM_017028449.1.
DR   RefSeq; XP_016883939.1; XM_017028450.1.
DR   RefSeq; XP_016883940.1; XM_017028451.1.
DR   RefSeq; XP_016883941.1; XM_017028452.1.
DR   RefSeq; XP_016883942.1; XM_017028453.1.
DR   PDB; 2D8I; NMR; -; A=835-935.
DR   PDB; 3KZD; X-ray; 1.30 A; A=841-930.
DR   PDB; 3KZE; X-ray; 1.80 A; A/B/C=841-930.
DR   PDB; 4GVC; X-ray; 1.54 A; A=841-930.
DR   PDB; 4GVD; X-ray; 1.85 A; A/B=841-930.
DR   PDB; 4K2O; X-ray; 2.15 A; A=429-702.
DR   PDB; 4K2P; X-ray; 1.98 A; A/B/C/D=429-702.
DR   PDB; 4NXP; X-ray; 2.30 A; A=841-930.
DR   PDB; 4NXQ; X-ray; 2.10 A; A/B/C=841-930.
DR   PDB; 4NXR; X-ray; 1.90 A; A=841-930.
DR   PDBsum; 2D8I; -.
DR   PDBsum; 3KZD; -.
DR   PDBsum; 3KZE; -.
DR   PDBsum; 4GVC; -.
DR   PDBsum; 4GVD; -.
DR   PDBsum; 4K2O; -.
DR   PDBsum; 4K2P; -.
DR   PDBsum; 4NXP; -.
DR   PDBsum; 4NXQ; -.
DR   PDBsum; 4NXR; -.
DR   AlphaFoldDB; Q13009; -.
DR   BMRB; Q13009; -.
DR   SMR; Q13009; -.
DR   BioGRID; 112930; 149.
DR   CORUM; Q13009; -.
DR   DIP; DIP-38309N; -.
DR   ELM; Q13009; -.
DR   IntAct; Q13009; 30.
DR   MINT; Q13009; -.
DR   STRING; 9606.ENSP00000286827; -.
DR   ChEMBL; CHEMBL3232697; -.
DR   GlyGen; Q13009; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q13009; -.
DR   PhosphoSitePlus; Q13009; -.
DR   BioMuta; TIAM1; -.
DR   DMDM; 152031709; -.
DR   EPD; Q13009; -.
DR   jPOST; Q13009; -.
DR   MassIVE; Q13009; -.
DR   MaxQB; Q13009; -.
DR   PaxDb; Q13009; -.
DR   PeptideAtlas; Q13009; -.
DR   ProteomicsDB; 24940; -.
DR   ProteomicsDB; 59099; -. [Q13009-1]
DR   Antibodypedia; 4172; 232 antibodies from 30 providers.
DR   DNASU; 7074; -.
DR   Ensembl; ENST00000286827.7; ENSP00000286827.3; ENSG00000156299.15. [Q13009-1]
DR   Ensembl; ENST00000455508.2; ENSP00000388217.2; ENSG00000156299.15. [Q13009-2]
DR   Ensembl; ENST00000541036.6; ENSP00000441570.2; ENSG00000156299.15. [Q13009-1]
DR   GeneID; 7074; -.
DR   KEGG; hsa:7074; -.
DR   MANE-Select; ENST00000541036.6; ENSP00000441570.2; NM_001353694.2; NP_001340623.1.
DR   UCSC; uc002yow.2; human. [Q13009-1]
DR   AGR; HGNC:11805; -.
DR   CTD; 7074; -.
DR   DisGeNET; 7074; -.
DR   GeneCards; TIAM1; -.
DR   HGNC; HGNC:11805; TIAM1.
DR   HPA; ENSG00000156299; Tissue enriched (brain).
DR   MalaCards; TIAM1; -.
DR   MIM; 600687; gene.
DR   MIM; 619908; phenotype.
DR   neXtProt; NX_Q13009; -.
DR   OpenTargets; ENSG00000156299; -.
DR   Orphanet; 528084; Non-specific syndromic intellectual disability.
DR   PharmGKB; PA36514; -.
DR   VEuPathDB; HostDB:ENSG00000156299; -.
DR   eggNOG; KOG3519; Eukaryota.
DR   GeneTree; ENSGT00940000156294; -.
DR   HOGENOM; CLU_000494_3_0_1; -.
DR   InParanoid; Q13009; -.
DR   OMA; QMQFYVP; -.
DR   OrthoDB; 25601at2759; -.
DR   PhylomeDB; Q13009; -.
DR   TreeFam; TF319686; -.
DR   PathwayCommons; Q13009; -.
DR   Reactome; R-HSA-193648; NRAGE signals death through JNK.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   Reactome; R-HSA-416482; G alpha (12/13) signalling events.
DR   Reactome; R-HSA-8980692; RHOA GTPase cycle.
DR   Reactome; R-HSA-9013148; CDC42 GTPase cycle.
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   Reactome; R-HSA-9013404; RAC2 GTPase cycle.
DR   Reactome; R-HSA-9013423; RAC3 GTPase cycle.
DR   Reactome; R-HSA-9032845; Activated NTRK2 signals through CDK5.
DR   SignaLink; Q13009; -.
DR   SIGNOR; Q13009; -.
DR   BioGRID-ORCS; 7074; 22 hits in 1161 CRISPR screens.
DR   ChiTaRS; TIAM1; human.
DR   EvolutionaryTrace; Q13009; -.
DR   GenomeRNAi; 7074; -.
DR   Pharos; Q13009; Tbio.
DR   PRO; PR:Q13009; -.
DR   Proteomes; UP000005640; Chromosome 21.
DR   RNAct; Q13009; protein.
DR   Bgee; ENSG00000156299; Expressed in cerebellar vermis and 198 other tissues.
DR   ExpressionAtlas; Q13009; baseline and differential.
DR   Genevisible; Q13009; HS.
DR   GO; GO:0044291; C:cell-cell contact zone; IDA:UniProtKB.
DR   GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0045202; C:synapse; IBA:GO_Central.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0019900; F:kinase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW.
DR   GO; GO:0090630; P:activation of GTPase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0007160; P:cell-matrix adhesion; IMP:UniProtKB.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0050772; P:positive regulation of axonogenesis; IBA:GO_Central.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; NAS:BHF-UCL.
DR   GO; GO:0032092; P:positive regulation of protein binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0065003; P:protein-containing complex assembly; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0016601; P:Rac protein signal transduction; IMP:UniProtKB.
DR   GO; GO:1904338; P:regulation of dopaminergic neuron differentiation; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0010717; P:regulation of epithelial to mesenchymal transition; IDA:BHF-UCL.
DR   GO; GO:2000050; P:regulation of non-canonical Wnt signaling pathway; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0051056; P:regulation of small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; IBA:GO_Central.
DR   GO; GO:0060071; P:Wnt signaling pathway, planar cell polarity pathway; NAS:ParkinsonsUK-UCL.
DR   CDD; cd00992; PDZ_signaling; 1.
DR   CDD; cd01230; PH1_Tiam1_2; 1.
DR   CDD; cd01255; PH2_Tiam1_2; 1.
DR   CDD; cd00160; RhoGEF; 1.
DR   Gene3D; 2.30.42.10; -; 1.
DR   Gene3D; 6.10.140.680; -; 1.
DR   Gene3D; 1.20.900.10; Dbl homology (DH) domain; 1.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 2.
DR   InterPro; IPR035899; DBL_dom_sf.
DR   InterPro; IPR000219; DH-domain.
DR   InterPro; IPR001331; GDS_CDC24_CS.
DR   InterPro; IPR001478; PDZ.
DR   InterPro; IPR036034; PDZ_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR003116; RBD_dom.
DR   InterPro; IPR043537; Tiam1/Tiam2/Sif.
DR   InterPro; IPR040655; TIAM1_CC-Ex.
DR   PANTHER; PTHR46001:SF1; RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR TIAM1; 1.
DR   PANTHER; PTHR46001; TIAM (MAMMALIAN TUMOR INVASION AND METASTASIS FACTOR) HOMOLOG; 1.
DR   Pfam; PF00595; PDZ; 1.
DR   Pfam; PF00169; PH; 2.
DR   Pfam; PF02196; RBD; 1.
DR   Pfam; PF00621; RhoGEF; 1.
DR   Pfam; PF18385; Tiam_CC_Ex; 1.
DR   SMART; SM00228; PDZ; 1.
DR   SMART; SM00233; PH; 2.
DR   SMART; SM00455; RBD; 1.
DR   SMART; SM00325; RhoGEF; 1.
DR   SUPFAM; SSF48065; DBL homology domain (DH-domain); 1.
DR   SUPFAM; SSF50156; PDZ domain-like; 1.
DR   SUPFAM; SSF50729; PH domain-like; 2.
DR   PROSITE; PS00741; DH_1; 1.
DR   PROSITE; PS50010; DH_2; 1.
DR   PROSITE; PS50106; PDZ; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS50898; RBD; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell junction; Cell membrane; Epilepsy;
KW   Guanine-nucleotide releasing factor; Intellectual disability;
KW   Isopeptide bond; Lipid-binding; Lipoprotein; Membrane; Myristate;
KW   Phosphoprotein; Reference proteome; Repeat; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000255"
FT   CHAIN           2..1591
FT                   /note="Rho guanine nucleotide exchange factor TIAM1"
FT                   /id="PRO_0000080976"
FT   DOMAIN          434..549
FT                   /note="PH 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          765..832
FT                   /note="RBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00262"
FT   DOMAIN          845..908
FT                   /note="PDZ"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00143"
FT   DOMAIN          1040..1234
FT                   /note="DH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00062"
FT   DOMAIN          1261..1397
FT                   /note="PH 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   REGION          1..78
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          298..379
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          393..422
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          939..1034
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1456..1482
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        9..23
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        24..45
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        48..74
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        298..327
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        340..379
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        958..977
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1011..1032
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1458..1473
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         231
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692"
FT   MOD_RES         356
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q60610"
FT   MOD_RES         358
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q60610"
FT   MOD_RES         695
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q60610"
FT   MOD_RES         829
FT                   /note="Phosphotyrosine; by NTRK2"
FT                   /evidence="ECO:0000250|UniProtKB:Q60610"
FT   MOD_RES         1323
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q60610"
FT   MOD_RES         1519
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q60610"
FT   LIPID           2
FT                   /note="N-myristoyl glycine"
FT                   /evidence="ECO:0000255"
FT   CROSSLNK        1404
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:25684205"
FT   CROSSLNK        1420
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:25684205"
FT   VAR_SEQ         715..739
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_055865"
FT   VAR_SEQ         797..831
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_055866"
FT   VARIANT         23
FT                   /note="R -> C (in NEDLDS; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:35240055"
FT                   /id="VAR_087427"
FT   VARIANT         247
FT                   /note="G -> R (in dbSNP:rs2070418)"
FT                   /id="VAR_051991"
FT   VARIANT         247
FT                   /note="G -> V (in dbSNP:rs2070417)"
FT                   /id="VAR_051992"
FT   VARIANT         328
FT                   /note="G -> V (in NEDLDS; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:35240055"
FT                   /id="VAR_087428"
FT   VARIANT         382
FT                   /note="G -> R (in NEDLDS; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:35240055"
FT                   /id="VAR_087429"
FT   VARIANT         678
FT                   /note="R -> C (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs1192824496)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035977"
FT   VARIANT         844
FT                   /note="Q -> H (in dbSNP:rs16987932)"
FT                   /evidence="ECO:0000269|PubMed:7731688"
FT                   /id="VAR_051993"
FT   VARIANT         862
FT                   /note="L -> F (in NEDLDS; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:35240055"
FT                   /id="VAR_087430"
FT   VARIANT         1007
FT                   /note="R -> H (in dbSNP:rs77092908)"
FT                   /evidence="ECO:0000269|PubMed:22100072"
FT                   /id="VAR_067424"
FT   VARIANT         1023
FT                   /note="D -> V (in dbSNP:rs75483199)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_071102"
FT   VARIANT         1339
FT                   /note="A -> V (in a colorectal cancer sample and NEDLDS;
FT                   somatic mutation; unknown pathological significance;
FT                   dbSNP:rs1319513413)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:35240055"
FT                   /id="VAR_035978"
FT   VARIANT         1547
FT                   /note="A -> E (in NEDLDS; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:35240055"
FT                   /id="VAR_087431"
FT   MUTAGEN         879
FT                   /note="K->E: Strongly reduces affinity for SDC1."
FT                   /evidence="ECO:0000269|PubMed:23395182"
FT   MUTAGEN         912
FT                   /note="K->E: Strongly reduces affinity for SDC1."
FT                   /evidence="ECO:0000269|PubMed:23395182"
FT   MUTAGEN         1404
FT                   /note="K->R: Decreased ubiquitination and increased
FT                   abundance."
FT                   /evidence="ECO:0000269|PubMed:25684205"
FT   MUTAGEN         1420
FT                   /note="K->R: Decreased ubiquitination and increased
FT                   abundance."
FT                   /evidence="ECO:0000269|PubMed:25684205"
FT   CONFLICT        24..25
FT                   /note="KH -> ND (in Ref. 1; AAA98443)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        247
FT                   /note="G -> M (in Ref. 1; AAA98443)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        881
FT                   /note="T -> I (in Ref. 3; AAI43981)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        951
FT                   /note="G -> D (in Ref. 1; AAA98443)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1018
FT                   /note="S -> N (in Ref. 1; AAA98443)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1040..1041
FT                   /note="KL -> NV (in Ref. 1; AAA98443)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1148
FT                   /note="S -> I (in Ref. 1; AAA98443)"
FT                   /evidence="ECO:0000305"
FT   STRAND          435..449
FT                   /evidence="ECO:0007829|PDB:4K2P"
FT   TURN            450..452
FT                   /evidence="ECO:0007829|PDB:4K2P"
FT   STRAND          453..456
FT                   /evidence="ECO:0007829|PDB:4K2P"
FT   STRAND          463..470
FT                   /evidence="ECO:0007829|PDB:4K2P"
FT   STRAND          473..477
FT                   /evidence="ECO:0007829|PDB:4K2P"
FT   STRAND          481..483
FT                   /evidence="ECO:0007829|PDB:4K2P"
FT   STRAND          492..496
FT                   /evidence="ECO:0007829|PDB:4K2P"
FT   STRAND          501..504
FT                   /evidence="ECO:0007829|PDB:4K2P"
FT   STRAND          512..518
FT                   /evidence="ECO:0007829|PDB:4K2P"
FT   STRAND          520..522
FT                   /evidence="ECO:0007829|PDB:4K2P"
FT   STRAND          524..528
FT                   /evidence="ECO:0007829|PDB:4K2P"
FT   HELIX           532..554
FT                   /evidence="ECO:0007829|PDB:4K2P"
FT   HELIX           559..587
FT                   /evidence="ECO:0007829|PDB:4K2P"
FT   TURN            588..590
FT                   /evidence="ECO:0007829|PDB:4K2P"
FT   HELIX           594..629
FT                   /evidence="ECO:0007829|PDB:4K2P"
FT   HELIX           636..640
FT                   /evidence="ECO:0007829|PDB:4K2P"
FT   HELIX           645..654
FT                   /evidence="ECO:0007829|PDB:4K2P"
FT   HELIX           659..667
FT                   /evidence="ECO:0007829|PDB:4K2P"
FT   STRAND          842..849
FT                   /evidence="ECO:0007829|PDB:3KZD"
FT   HELIX           850..852
FT                   /evidence="ECO:0007829|PDB:4NXR"
FT   TURN            855..858
FT                   /evidence="ECO:0007829|PDB:3KZE"
FT   STRAND          859..865
FT                   /evidence="ECO:0007829|PDB:3KZD"
FT   STRAND          867..870
FT                   /evidence="ECO:0007829|PDB:3KZD"
FT   STRAND          872..878
FT                   /evidence="ECO:0007829|PDB:3KZD"
FT   HELIX           883..886
FT                   /evidence="ECO:0007829|PDB:3KZD"
FT   STRAND          894..898
FT                   /evidence="ECO:0007829|PDB:3KZD"
FT   HELIX           903..905
FT                   /evidence="ECO:0007829|PDB:3KZD"
FT   HELIX           908..916
FT                   /evidence="ECO:0007829|PDB:3KZD"
FT   STRAND          917..926
FT                   /evidence="ECO:0007829|PDB:3KZD"
SQ   SEQUENCE   1591 AA;  177508 MW;  0DAFBEE9A84B3452 CRC64;
     MGNAESQHVE HEFYGEKHAS LGRKHTSRSL RLSHKTRRTR HASSGKVIHR NSEVSTRSSS
     TPSIPQSLAE NGLEPFSQDG TLEDFGSPIW VDRVDMGLRP VSYTDSSVTP SVDSSIVLTA
     ASVQSMPDTE ESRLYGDDAT YLAEGGRRQH SYTSNGPTFM ETASFKKKRS KSADIWREDS
     LEFSLSDLSQ EHLTSNEEIL GSAEEKDCEE ARGMETRASP RQLSTCQRAN SLGDLYAQKN
     SGVTANGGPG SKFAGYCRNL VSDIPNLANH KMPPAAAEET PPYSNYNTLP CRKSHCLSEG
     ATNPQISHSN SMQGRRAKTT QDVNAGEGSE FADSGIEGAT TDTDLLSRRS NATNSSYSPT
     TGRAFVGSDS GSSSTGDAAR QGVYENFRRE LEMSTTNSES LEEAGSAHSD EQSSGTLSSP
     GQSDILLTAA QGTVRKAGAL AVKNFLVHKK NKKVESATRR KWKHYWVSLK GCTLFFYESD
     GRSGIDHNSI PKHAVWVENS IVQAVPEHPK KDFVFCLSNS LGDAFLFQTT SQTELENWIT
     AIHSACATAV ARHHHKEDTL RLLKSEIKKL EQKIDMDEKM KKMGEMQLSS VTDSKKKKTI
     LDQIFVWEQN LEQFQMDLFR FRCYLASLQG GELPNPKRLL AFASRPTKVA MGRLGIFSVS
     SFHALVAART GETGVRRRTQ AMSRSASKRR SRFSSLWGLD TTSKKKQGRP SINQVFGEGT
     EAVKKSLEGI FDDIVPDGKR EKEVVLPNVH QHNPDCDIWV HEYFTPSWFC LPNNQPALTV
     VRPGDTARDT LELICKTHQL DHSAHYLRLK FLIENKMQLY VPQPEEDIYE LLYKEIEICP
     KVTQSIHIEK SDTAADTYGF SLSSVEEDGI RRLYVNSVKE TGLASKKGLK AGDEILEINN
     RAADALNSSM LKDFLSQPSL GLLVRTYPEL EEGVELLESP PHRVDGPADL GESPLAFLTS
     NPGHSLCSEQ GSSAETAPEE TEGPDLESSD ETDHSSKSTE QVAAFCRSLH EMNPSDQSPS
     PQDSTGPQLA TMRQLSDADK LRKVICELLE TERTYVKDLN CLMERYLKPL QKETFLTQDE
     LDVLFGNLTE MVEFQVEFLK TLEDGVRLVP DLEKLEKVDQ FKKVLFSLGG SFLYYADRFK
     LYSAFCASHT KVPKVLVKAK TDTAFKAFLD AQNPKQQHSS TLESYLIKPI QRILKYPLLL
     RELFALTDAE SEEHYHLDVA IKTMNKVASH INEMQKIHEE FGAVFDQLIA EQTGEKKEVA
     DLSMGDLLLH TTVIWLNPPA SLGKWKKEPE LAAFVFKTAV VLVYKDGSKQ KKKLVGSHRL
     SIYEDWDPFR FRHMIPTEAL QVRALASADA EANAVCEIVH VKSESEGRPE RVFHLCCSSP
     ESRKDFLKAV HSILRDKHRR QLLKTESLPS SQQYVPFGGK RLCALKGARP AMSRAVSAPS
     KSLGRRRRRL ARNRFTIDSD AVSASSPEKE SQQPPGGGDT DRWVEEQFDL AQYEEQDDIK
     ETDILSDDDE FCESVKGASV DRDLQERLQA TSISQRERGR KTLDSHASRM AQLKKQAALS
     GINGGLESAS EEVIWVRRED FAPSRKLNTE I
//
